+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Brain Tumor Drugs Global Market Report 2024

  • PDF Icon

    Report

  • 175 Pages
  • February 2024
  • Region: Global
  • The Business Research Company
  • ID: 5939595
The brain tumor drugs market size has grown strongly in recent years. It will grow from $3.55 billion in 2023 to $3.81 billion in 2024 at a compound annual growth rate (CAGR) of 7.3%. The historical growth can be attributed to several factors, including a rising prevalence of neurological disorders, increased healthcare expenditure, a higher number of approvals for oncology (cancer) drugs, an upsurge in pharmaceutical research and development (R&D) expenditure, and advancements in cancer drug discovery.

The brain tumor drugs market size is expected to see strong growth in the next few years. It will grow to $5.01 billion in 2028 at a compound annual growth rate (CAGR) of 7.1%. Forecasted growth is attributed to rising cancer rates, increased healthcare spending, a growing elderly population, a robust drug pipeline, and revised FDA regulations for biologics. Major trends include investing in drug combinations for brain tumor treatment, adopting phase zero clinical trials for efficacy improvement, using technology in drug delivery for enhanced effectiveness, focusing on expanding cell and gene therapy, and engaging in strategic mergers and acquisitions.

The primary catalyst fueling the expansion of the Brain Tumor drugs market is the escalating prevalence of Neurological Disorders on a global scale. These disorders have become increasingly prevalent due to factors such as longer life expectancy, heightened exposure to infections, and sedentary lifestyles. For instance, as reported by the National Brain Tumor Society, approximately 700,000 individuals in the United States are currently affected by primary brain tumors, with an additional 86,000 expected to receive diagnoses. This growing population of individuals with neurological disorders, including brain tumors, is directly contributing to the increased demand for drugs utilized in their treatment, thereby fostering the growth of the brain tumor drugs market.

The surge in the number of patients undergoing chemotherapy is poised to drive the continued expansion of brain tumor drugs. Chemotherapy, a vital medical approach employing potent drugs to target and eradicate rapidly dividing cells such as cancer cells, remains a cornerstone treatment for brain tumors. The development and accessibility of effective chemotherapy drugs significantly influence the overall success of treatment regimens. The efficacy of chemotherapy profoundly impacts patient survival rates and enhances their quality of life, exerting a substantial influence on the market landscape. For instance, based on data from the Centers for Disease Control and Prevention in July 2023, over 1 million cancer patients in the United States undergo chemotherapy or radiation therapy annually. Consequently, the escalating number of patients opting for chemotherapy serves as a pivotal driver propelling the growth trajectory of the brain tumor drugs market.

Companies within the brain tumor drugs market are increasingly turning towards nanotechnology for treatment methodologies. Nanoparticles are being utilized as carriers for drugs, delivering them directly to cancer cells or into the tumor, yielding advantages such as reduced drug dosage, enhanced shelf life, and minimized toxicity. Some nanodrugs have proven effective in surmounting the blood-brain barrier, a historically significant challenge in treating brain tumors. Notably, nanoparticles such as Liposomes have facilitated targeted drug delivery to the core of cancer cells. Moreover, when coated with transferrin, these particles can breach the blood-brain barrier. Esteemed industry players such as GE Healthcare, Sigma-Tau Pharmaceuticals Inc., Johnson & Johnson, Merck & Company Inc., Pfizer, Inc., and Celgene Corporation are actively embracing this technology to advance medication and treatment techniques.

Key industry entities within the brain tumor drugs market are heavily invested in the development and approval of novel drugs, aiming to gain a competitive advantage. Drug approvals represent the regulatory process by which government health agencies authorize the marketing, sale, and prescription of new medications for specific medical conditions. For example, in June 2022, the United States Food and Drug Administration granted accelerated approval for a novel treatment combination incorporating the oral drugs dabrafenib (Tafinlar) and trametinib (Mekinist) for advanced brain tumors exhibiting the BRAF V600E mutation. This approval extends to both adult and pediatric patients with high- and low-grade gliomas that have progressed post-prior treatments. Encouraging results from clinical trials revealed significant tumor reduction among patients receiving the combination therapy. Notably, positive responses were observed in 33% of high-grade glioma patients, 50% of low-grade glioma patients, and 25% of pediatric glioma patients. The BRAF V600E mutation is prevalent across various glioma types, including low-grade gliomas, pleomorphic xanthoastrocytomas (PXA), gangliogliomas, and pilocytic astrocytomas.

In December 2021, Sanofi, a French pharmaceutical company, completed the acquisition of Amunix Pharmaceuticals Inc. for a total of $1 billion. This strategic move positions Sanofi to advance its efforts in developing potentially transformative cancer therapies, particularly in the field of immuno-oncology. Amunix Pharmaceuticals Inc., a U.S.-based pharmaceutical company, brings valuable assets, including brain tumor drugs, to bolster Sanofi's capabilities in the oncology space.

Major companies operating in the brain tumor drugs market report are F. Hoffmann-La Roche Ltd., Novartis AG, Amgen Inc., Pfizer Inc., Merck & Co. Inc., CordenPharma, Eisai Co., Ltd., Emcure Pharmaceuticals Limited, AstraZeneca, Y-mAbs Therapeutics, Roche India, Novartis Oncology, Arlak Biotech, Healthkind Labs Pvt. Ltd., SwisscheM Healthcare Pvt.Ltd., Apikos Pharma, Kolaz Biotech, CStone Pharma, CARsgen Therapeutics, JW Therapeutics, BeiGene, Takeda Pharmaceuticals (Japan), Astellas Pharma Inc., Otsuka Pharmaceutical Co., Ltd., Daiichi Pharmaceutical and Sankyo, AQVIDA GmbH, Baxter International Inc. (UK), AstraZeneca PLC, GlaxoSmithKline PLC, F. Hoffmann-La Roche AG, Veropharm, Biocad, Bristol-Myers Squibb, Celon Pharma, Celgene Corporation, Johnson & Johnson, Eli Lilly and Company, Sandoz AG, Eurofarma Laboratórios S.A., TUTEUR Argentina, The Takeda Pharmaceutical Company Limited, Pierre Fabre Group, Celnova Pharma, Pfizer S.R.L., Teva Pharmaceutical Industries Ltd., BIOPHARMA-MEA, NeoTX, AID Genomics Limited, GlaxoSmithKline PLC, Julphar, Sanofi, Novo Nordisk A/S, Bayer, Kitov Pharma Limited, CureTech Ltd., Neopharma, Eurolab, Aspen, Adcock Ingram.

North America was the largest region in the brain tumor drugs market in 2023. Middle East is expected to be the fastest-growing region in the global brain tumor drugs market share during the forecast period. The regions covered in the brain tumor drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the brain tumor drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.

Key drugs in the realm of brain tumor treatment include temozolomide, carmustine, cisplatin, bevacizumab, gefitinib, and erlotinib. Temozolomide, for instance, is designed to treat specific types of brain cancer such as glioblastomamultiforme and anaplastic astrocytoma. These drugs fall under the category of antineoplastics, focusing on combating cancer. Various types of brain tumors, such as medulloblastoma, astrocytoma, oligodendroglioma, primitive neuroectodermal (PNET), and others such as glioma, acoustic neuroma, and meningioma, are addressed using these drugs. The sectors benefiting from these treatments include hospital pharmacies, clinics, and other healthcare facilities.

The brain tumor drugs market research report is one of a series of new reports that provides brain tumor drugs market statistics, including brain tumor drugs industry global market size, regional shares, competitors with a brain tumor drugs market share, detailed brain tumor drugs market segments, market trends and opportunities, and any further data you may need to thrive in the brain tumor drugs industry. This brain tumor drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The brain tumor drugs market consists of sales Afinitor (Everolimus), Afinitor Disperz (Everolimus), Belzutifan, and Bevacizumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Table of Contents

1. Executive Summary2. Brain Tumor Drugs Market Characteristics3. Brain Tumor Drugs Market Trends and Strategies
4. Brain Tumor Drugs Market - Macro Economic Scenario
4.1. Impact of High Inflation on the Market
4.2. Ukraine-Russia War Impact on the Market
4.3. COVID-19 Impact on the Market
5. Global Brain Tumor Drugs Market Size and Growth
5.1. Global Brain Tumor Drugs Market Drivers and Restraints
5.1.1. Drivers of the Market
5.1.2. Restraints of the Market
5.2. Global Brain Tumor Drugs Historic Market Size and Growth, 2018-2023, Value ($ Billion)
5.3. Global Brain Tumor Drugs Forecast Market Size and Growth, 2023-2028, 2033F, Value ($ Billion)
6. Brain Tumor Drugs Market Segmentation
6.1. Global Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Medulloblastoma
  • Astrocytoma
  • Oligodendroglioma
  • Primitive Neuroectodermal (PNET)
  • Others (Glioma, Acoustic Neuroma, Meningioma)
6.2. Global Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Temozolomide
  • Carmustine
  • Cisplatin
  • Bevacizumab
  • Geftinib
  • Erlotinib
6.3. Global Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
  • Hospital Pharmacies
  • Clinics
  • Other End-Users
7. Brain Tumor Drugs Market Regional and Country Analysis
7.1. Global Brain Tumor Drugs Market, Split by Region, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
7.2. Global Brain Tumor Drugs Market, Split by Country, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8. Asia-Pacific Brain Tumor Drugs Market
8.1. Asia-Pacific Brain Tumor Drugs Market Overview
Region Information, Impact of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.3. Asia-Pacific Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
8.4. Asia-Pacific Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
9. China Brain Tumor Drugs Market
9.1. China Brain Tumor Drugs Market Overview
9.2. China Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.3. China Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
9.4. China Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F,$ Billion
10. India Brain Tumor Drugs Market
10.1. India Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.2. India Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
10.3. India Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11. Japan Brain Tumor Drugs Market
11.1. Japan Brain Tumor Drugs Market Overview
11.2. Japan Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.3. Japan Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
11.4. Japan Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12. Australia Brain Tumor Drugs Market
12.1. Australia Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.2. Australia Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
12.3. Australia Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13. Indonesia Brain Tumor Drugs Market
13.1. Indonesia Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.2. Indonesia Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
13.3. Indonesia Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14. South Korea Brain Tumor Drugs Market
14.1. South Korea Brain Tumor Drugs Market Overview
14.2. South Korea Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.3. South Korea Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
14.4. South Korea Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15. Western Europe Brain Tumor Drugs Market
15.1. Western Europe Brain Tumor Drugs Market Overview
15.2. Western Europe Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.3. Western Europe Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
15.4. Western Europe Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16. UK Brain Tumor Drugs Market
16.1. UK Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.2. UK Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
16.3. UK Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17. Germany Brain Tumor Drugs Market
17.1. Germany Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.2. Germany Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
17.3. Germany Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18. France Brain Tumor Drugs Market
18.1. France Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.2. France Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
18.3. France Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19. Italy Brain Tumor Drugs Market
19.1. Italy Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.2. Italy Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
19.3. Italy Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20. Spain Brain Tumor Drugs Market
20.1. Spain Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.2. Spain Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
20.3. Spain Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21. Eastern Europe Brain Tumor Drugs Market
21.1. Eastern Europe Brain Tumor Drugs Market Overview
21.2. Eastern Europe Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.3. Eastern Europe Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
21.4. Eastern Europe Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22. Russia Brain Tumor Drugs Market
22.1. Russia Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.2. Russia Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
22.3. Russia Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23. North America Brain Tumor Drugs Market
23.1. North America Brain Tumor Drugs Market Overview
23.2. North America Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.3. North America Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
23.4. North America Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24. USA Brain Tumor Drugs Market
24.1. USA Brain Tumor Drugs Market Overview
24.2. USA Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.3. USA Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
24.4. USA Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25. Canada Brain Tumor Drugs Market
25.1. Canada Brain Tumor Drugs Market Overview
25.2. Canada Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.3. Canada Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
25.4. Canada Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26. South America Brain Tumor Drugs Market
26.1. South America Brain Tumor Drugs Market Overview
26.2. South America Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.3. South America Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
26.4. South America Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27. Brazil Brain Tumor Drugs Market
27.1. Brazil Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.2. Brazil Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
27.3. Brazil Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28. Middle East Brain Tumor Drugs Market
28.1. Middle East Brain Tumor Drugs Market Overview
28.2. Middle East Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.3. Middle East Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
28.4. Middle East Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29. Africa Brain Tumor Drugs Market
29.1. Africa Brain Tumor Drugs Market Overview
29.2. Africa Brain Tumor Drugs Market, Segmentation by Type, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.3. Africa Brain Tumor Drugs Market, Segmentation by Drugs, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
29.4. Africa Brain Tumor Drugs Market, Segmentation by End User, Historic and Forecast, 2018-2023, 2023-2028F, 2033F, $ Billion
30. Brain Tumor Drugs Market Competitive Landscape and Company Profiles
30.1. Brain Tumor Drugs Market Competitive Landscape
30.2. Brain Tumor Drugs Market Company Profiles
30.2.1. F. Hoffmann-La Roche Ltd
30.2.1.1. Overview
30.2.1.2. Products and Services
30.2.1.3. Strategy
30.2.1.4. Financial Performance
30.2.2. Novartis AG
30.2.2.1. Overview
30.2.2.2. Products and Services
30.2.2.3. Strategy
30.2.2.4. Financial Performance
30.2.3. Amgen Inc.
30.2.3.1. Overview
30.2.3.2. Products and Services
30.2.3.3. Strategy
30.2.3.4. Financial Performance
30.2.4. Pfizer Inc.
30.2.4.1. Overview
30.2.4.2. Products and Services
30.2.4.3. Strategy
30.2.4.4. Financial Performance
30.2.5. Merck & Co. Inc.
30.2.5.1. Overview
30.2.5.2. Products and Services
30.2.5.3. Strategy
30.2.5.4. Financial Performance
31. Brain Tumor Drugs Market Other Major and Innovative Companies
31.1. CordenPharma
31.2. Eisai Co., Ltd.
31.3. Emcure Pharmaceuticals Limited
31.4. AstraZeneca
31.5. Y-mAbs Therapeutics
31.6. Roche India
31.7. Novartis Oncology
31.8. Arlak Biotech
31.9. Healthkind Labs Pvt. Ltd.
31.10. SwisscheM Healthcare Pvt.Ltd
31.11. Apikos Pharma
31.12. Kolaz Biotech
31.13. CStone Pharma
31.14. CARsgen Therapeutics
31.15. JW Therapeutics
32. Global Brain Tumor Drugs Market Competitive Benchmarking33. Global Brain Tumor Drugs Market Competitive Dashboard34. Key Mergers and Acquisitions in the Brain Tumor Drugs Market
35. Brain Tumor Drugs Market Future Outlook and Potential Analysis
35.1 Brain Tumor Drugs Market in 2028 - Countries Offering Most New Opportunities
35.2 Brain Tumor Drugs Market in 2028 - Segments Offering Most New Opportunities
35.3 Brain Tumor Drugs Market in 2028 - Growth Strategies
35.3.1 Market Trend-based Strategies
35.3.2 Competitor Strategies
36. Appendix
36.1. Abbreviations
36.2. Currencies
36.3. Historic and Forecast Inflation Rates
36.4. Research Inquiries
36.5. About the Analyst
36.6. Copyright and Disclaimer

Executive Summary

Brain Tumor Drugs Global Market Report 2024 provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on brain tumor drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
  • Understand how the market has been affected by the coronavirus and how it is responding as the impact of the virus abates.
  • Assess the Russia-Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
  • Measure the impact of high global inflation on market growth.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis.
  • Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for brain tumor drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? This report answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:
  • The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.
  • The impact of higher inflation in many countries and the resulting spike in interest rates.
  • The continued but declining impact of COVID-19 on supply chains and consumption patterns.
  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Report Scope

Markets Covered:
1) By Drugs: Temozolomide; Bevacizumab; Other Drugs
2) By End-user: Hospital Pharmacies; Retail Pharmacies/Drug Stores; Other End-Users

Key Companies Mentioned: F. Hoffmann-La Roche Ltd; Novartis AG; Amgen Inc.; Pfizer Inc.; Merck & Co. Inc.

Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain

Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa

Time Series: Five years historic and ten years forecast

Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita

Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments

Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes

Delivery Format: PDF, Word and Excel Data Dashboard

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • F. Hoffmann-La Roche Ltd
  • Novartis AG
  • Amgen Inc.
  • Pfizer Inc.
  • Merck & Co. Inc.
  • CordenPharma
  • Eisai Co., Ltd.
  • Emcure Pharmaceuticals Limited
  • AstraZeneca
  • Y-mAbs Therapeutics
  • Roche India
  • Novartis Oncology
  • Arlak Biotech
  • Healthkind Labs Pvt. Ltd.
  • SwisscheM Healthcare Pvt.Ltd
  • Apikos Pharma
  • Kolaz Biotech
  • CStone Pharma
  • CARsgen Therapeutics
  • JW Therapeutics
  • BeiGene
  • Takeda Pharmaceuticals (Japan)
  • Astellas Pharma Inc
  • Otsuka Pharmaceutical Co., Ltd
  • Daiichi Pharmaceutical and Sankyo
  • AQVIDA GmbH
  • Baxter International Inc. (UK)
  • AstraZeneca plc
  • GlaxoSmithKline plc
  • F. Hoffmann-La Roche AG
  • Veropharm
  • Biocad
  • Bristol-Myers Squibb
  • Celon Pharma
  • Celgene Corporation
  • Johnson & Johnson
  • Eli Lilly and Company
  • Sandoz AG
  • Eurofarma Laboratórios S.A.
  • TUTEUR Argentina
  • The Takeda Pharmaceutical Company Limited
  • Pierre Fabre Group
  • Celnova Pharma
  • Pfizer S.R.L.
  • Teva Pharmaceutical Industries Ltd.
  • BIOPHARMA-MEA
  • NeoTX
  • AID Genomics Limited
  • GlaxoSmithKline plc
  • Julphar
  • Sanofi
  • Novo Nordisk A/S
  • Bayer
  • Kitov Pharma Limited
  • CureTech Ltd.
  • Neopharma
  • Eurolab
  • Aspen
  • Adcock Ingram.

Methodology

Loading
LOADING...